Adjunctive Statin Therapy in Patients with Covid-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
| Autor: | Florêncio de Mesquita C; Department of Medicine, Federal University of Pernambuco, Recife, Brazil., Rivera A; Department of Medicine, Nove de Julho University, São Bernardo do Campo, Brazil. Electronic address: andre.riveraa01@gmail.com., Araújo B; Department of Medicine, Nove de Julho University, São Bernardo do Campo, Brazil., Durães VL; Department of Medicine, Federal University of Pernambuco, Recife, Brazil., Queiroz I; Department of Medicine, Catholic University of Pernambuco, Pernambuco, Brazil., Carvalho VH; Department of Medicine, University of Campinas, São Paulo, Brazil., Haque T; Division of General Internal Medicine, Brigham and Women's Hospital Harvard Medical School, Boston, Mass., Bes TM; Department of Infectious Diseases, Boston Medical Center, Boston, Mass. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The American journal of medicine [Am J Med] 2024 Oct; Vol. 137 (10), pp. 966-973.e11. Date of Electronic Publication: 2024 Jun 10. |
| DOI: | 10.1016/j.amjmed.2024.06.002 |
| Abstrakt: | Background: The efficacy and safety of adjunctive statin therapy in hospitalized patients with coronavirus disease 2019 (Covid-19) remains uncertain. Methods: We systematically searched Medline, Embase, Cochrane, and ClinicalTrials.gov databases from inception to late April 2024 for randomized controlled trials (RCTs) comparing statin versus no statin use in patients hospitalized with Covid-19. We pooled risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) applying a random-effects model. R version 4.3.1 was used for statistical analyses. Results: We included 7 RCTs comprising 4,262 patients, of whom 2,645 (62%) were randomized to receive statin therapy. Compared with no statin, statin use significantly reduced case-fatality rate (RR 0.88; 95% CI 0.80-0.98; I 2 = 0%). In a time-to-event analysis, we found similar results (HR 0.86; 95% CI 0.75-0.99; I 2 = 0%). Statin use also significantly reduced World Health Organization (WHO) scale at 14 days (mean difference -0.27; 95% CI -0.54 to -0.01; I 2 = 0%). There was no statistically significant difference between the two groups in length of hospital stay, elevation of liver enzymes, and C-reactive protein levels. Conclusions: In patients hospitalized with Covid-19, statins significantly reduced case-fatality rate and WHO scale score. Registration: A prospective register was recorded in International Prospective Register of Systematic Reviews (PROSPERO) with the number CRD42023479007. (Copyright © 2024 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|